Updated results from a first-in-human phase 1,2 study of ACE-106, a highly selective and potentially best-in-class PARP1 inhibitor in advanced solid tumors

ACE-106 - Acerand Therap

Xingyun Cai1; Jian Zhang2; Yu Chen3; Yanxia Shi4; Wei Wang5; Zhanhong Chen6; Jiongjie Chen1

Mar 18, 2026